Improving the health and quality of life of patients is our goal at the research-driven pharmaceutical company, Boehringer Ingelheim. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies.
Some 50,000 employees create value through innovation every day for the three business areas: human pharmaceuticals; animal health; and, biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of around £18.1 billion and our investment in research corresponded to 17% of net sales.
We concentrate on developing innovative therapies that can extend patients? lives. In 2017, we spent around ?3.1 billion on research and development, with three sites for human health and a network of more than 20 sites for animal health.
In animal health, Boehringer Ingelheim stands for advanced prevention. Our animal health business is now the second largest in the world, with more than 200 products for dogs, cats, horses, pigs, cattle and poultry.
We are also a world-leading contract manufacturer of biopharmaceuticals, using cell cultures and micro-organisms at plants in Austria, China, Germany and the USA.